In summary, the meta-analysis of PD-1/PD-L1 inhibitors in the treatment of R/R DLBCL indicates limited therapeutic efficacy while demonstrating consistent safety profiles. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.